고중성지방혈증을 동반한 지방간 환자 치험 1례
Case Report of a Patient Diagnosed with Fatty Liver Accompanied by Hypertriglyceridemia
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: This study aimed to identify whether herbal medicine improves the clinical symptoms and abnormal blood tests of a patient with fatty liver accompanied by hypertriglyceridemia. Methods: A 44-year-old man with fatty liver and hypertriglyceridemia was prescribed Saenggangunbi-tang from July 20, 2020, to November 11, 2020, to reduce fatigue and to improve laboratory findings, such as liver enzymes and the lipid profile. We observed changes in symptoms, serum levels of liver enzymes, and the lipid profile during about 4-month treatment. We also recorded changes in the bioelectrical impedance analyzer findings during that time. Results: In this case study, an approximately 4-month treatment with Saenggangunbi-tang led to considerable improvement in laboratory findings and visceral fat area. In particular, the patient experienced a noticeable decrease in triglyceride levels compared with the baseline parameters of the first visit. In addition, no side effects—including weight gain and liver enzyme increases—were observed during treatment. Conclusion: This study suggests that appropriately prescribed herbal medicine is a therapeutic option to manage fatty liver combined with hypertriglyceridemia.
Abstract
Objectives: This study aimed to identify whether herbal medicine improves the clinical symptoms and abnormal blood tests of a patient with fatty liver accompanied by hypertriglyceridemia. Methods: A 44-year-old man with fatty liver and hypertriglyceridemia was prescribed Saenggangunbi-tang from July 20, 2020, to November 11, 2020, to reduce fatigue and to improve laboratory findings, such as liver enzymes and the lipid profile. We observed changes in symptoms, serum levels of liver enzymes, and the lipid profile during about 4-month treatment. We also recorded changes in the bioelectrical impedance analyzer findings during that time. Results: In this case study, an approximately 4-month treatment with Saenggangunbi-tang led to considerable improvement in laboratory findings and visceral fat area. In particular, the patient experienced a noticeable decrease in triglyceride levels compared with the baseline parameters of the first visit. In addition, no side effects—including weight gain and liver enzyme increases—were observed during treatment. Conclusion: This study suggests that appropriately prescribed herbal medicine is a therapeutic option to manage fatty liver combined with hypertriglyceridemia.
참고문헌 (30)
- European Association for the Study of Liver, "EASL clinical practical guidelines:management of alcoholic liver disease", J Hepatol, 57(2), pp.399~420 (2012)
- Machado MV, "Zakim and Boyer's Hepatology", pp.369~ (2018), Elsevier
- 윤승규, "지방간의 진단과 치료", 대한내과학회지, 76(6), pp.677~679 (2009), 대한내과학회
- den Boer M, "Hepatic steatosis:a mediator of the metabolic syndrome. Lessons from animal models", Arterioscler Thromb Vasc Biol, 24(4), pp.644~649 (2004)
- Tomizawa M, "Triglyceride is strongly associated with nonalcoholic fatty liver disease among markers of hyperlipidemia and diabetes", Biomed Rep, 2(5), pp.633~636 (2014)
- 한지민, "Differing Associations between Fatty Liver and Dyslipidemia According to the Degree of Hepatic Steatosis in Korea", 지질·동맥경화학회지, 8(2), pp.258~266 (2019), 한국지질동맥경화학회[DOI]
- Loria P, "Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology", Atherosclerosis, 232(1), pp.99~109 (2014)
- Boullart AC, "Serum triglycerides and risk of cardiovascular disease", Biochim Biophys Acta, 1821(5), pp.867~875 (2012)
- Murphy MJ, "Hypertriglyceridemia and acute pancreatitis", JAMA Intern Med, 173(2), pp.162~164 (2013)
- 정지선, "Prevalence and Clinical Characteristics of Dyslipidemia in Koreans", Endocrinology and Metabolism, 32(1), pp.30~35 (2017), 대한내분비학회
- Eslam M, "A New Definition for Metabolic Associated Fatty Liver Disease:An International Expert Consensus Statement", J Hepatol, 73(1), pp.202~209 (2020)
- Stone NJ, "2013 ACC", AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults:A Report of the American College of Cardiology, Circulation, pp.2014, 129(2)[DOI]
- Zeng J, "Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease", World J Gastroenterol, 26(15), pp.1792~1804 (2020)
- Struben VM, "Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds", Am J Med, 108(1), pp.9~13 (2000)
- Salazar MR, "Relation among the plasma triglyceride", high-density lipoprotein cholesterol concentration ratio, insulin resistance, and associated cardio-metabolic risk factors in men and women, 2012, pp.109(12), 1749~1753
- Cone CJ, "Hepatotoxicity associated with metformin therapy in treatment of type 2 diabetes mellitus with nonalcoholic fatty liver disease", Ann Pharmacother, 44(10), pp.1655~1659 (2010)
- Lee BW, "Management of patients with nonalcoholic fatty liver disease with lifestyle modification", Korean Diabetes, 19(2), pp.82~87 (2018)
- Woo HJ, "Oriental Internal Medicine on Hepatobiliary System, Hematology and Toxicology", pp.321~328 (2016), Nado
- Choi ES, "A Case Report of Adolescent Nonalcoholic Fatty Liver Disease (NAFLD) with Severe Obesity", J Int Korean Med, (spr), pp.89~95 (2015)
- Kang KR, "A Male Nonalcoholic Steatohepatitis (NASH) Patient Diagnosed with Moderate Fibrosis using Fibroscan-a Case Report", J Int Korean Med, (spr), pp.120~126 (2015)
- 김하연, "대사증후군을 동반한 비알코올성 지방간염 치험 1례", 대한한방내과학회지, 38(2), pp.125~130 (2017), 대한한방내과학회
- Sin SM, "Saenggangeonbi-tang's effects on metabolic syndrome", J Int Korean Med, (fal), pp.65~70 (2008)
- 이성노, "간정격 시술 및 생간건비탕 투여가 간기능 및 비만도 변화에 미치는 영향", Journal of Acupuncture Research, 25(6), pp.47~54 (2008), 대한침구의학회
- Whitfield JB, "Gamma glutamyl transferase", Crit Rev Clin Lab Sci, 38(4), pp.263~355 (2001)
- Hsueh WA, "Role of endothelial dysfunction in insulin resistance", Am J Cardiol, 92(4), pp.10~17 (2003)
- Fujii H, "Frequently abnormal serum gamma-glutamyl transferase activity is associated with future development of fatty liver:a retrospective cohort study", BMC gastroenterology, 20(1), pp.1~9 (2020)
- Tahan V, "Serum gamma-glutamyltranspeptidase distinguishes non-alcoholic fatty liver disease at high risk", Hepatogastroenterol, 55(85), pp.1433~1438 (2008)
- Mofrad P, "Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values", Hepatol, 37(6), pp.1286~1292 (2003)
- Noureddin M, "Nonalcoholic fatty liver disease:Indications for liver biopsy and noninvasive biomarkers", Clin Liver Dis, 1(4), pp.104~107 (2012)
- Marotta T, "Triglyceride- to-HDL-cholesterol ratio and metabolic syndrome as contributors to cardiovascular risk in overweight patients", Obesity, 18(8), pp.1608~1613 (2010)